Chapter title |
Inhibition of PI3K-Akt-mTOR Signaling in Glioblastoma by mTORC1/2 Inhibitors.
|
---|---|
Chapter number | 22 |
Book title |
mTOR
|
Published in |
Methods in molecular biology, September 2011
|
DOI | 10.1007/978-1-61779-430-8_22 |
Pubmed ID | |
Book ISBNs |
978-1-61779-429-2, 978-1-61779-430-8
|
Authors |
Fan QW, Weiss WA, Qi-Wen Fan, William A. Weiss, Fan, Qi-Wen, Weiss, William A. |
Editors |
Thomas Weichhart |
Abstract |
Amplification of the gene encoding the epidermal growth factor receptor (EGFR) occurs commonly in glioblastoma (GBM), leading to activation of downstream kinases, including phosphatidylinositol 3'-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR). A serine-threonine kinase, mTOR controls cell growth by regulating mRNA translation, metabolism, and autophagy; acting as both a downstream effector and upstream regulator of PI3K. These signaling functions are distributed between at least two distinct complexes, mTORC1 and mTORC2 with respect to pathway specificity. We have investigated mTOR signaling in glioma cells with the allosteric mTORC1 inhibitor rapamycin, the mTORC1/2 inhibitor Ku-0063794, a dual PI3K/mTORC1/2 kinase inhibitor PI-103, and siRNA against raptor, rictor, or mTOR, and evaluated the value of mTOR inhibitors for the treatment of glioblastoma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 61 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 19% |
Student > Ph. D. Student | 9 | 14% |
Student > Bachelor | 7 | 11% |
Student > Master | 6 | 10% |
Other | 3 | 5% |
Other | 11 | 17% |
Unknown | 15 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 16 | 25% |
Medicine and Dentistry | 11 | 17% |
Biochemistry, Genetics and Molecular Biology | 10 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Neuroscience | 2 | 3% |
Other | 3 | 5% |
Unknown | 18 | 29% |